Table 1 Epidemiological and clinical features according to diagnosis at last follow-up
From: Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Total population n = 125 | Relapsing ON n = 61 | NMOSD-like phenotype n = 41 | bRelapsing TM n = 11 | cMADEM/brainstem S n = 5 | dMS-like/optico-spinal phenotype n = 7 | |
|---|---|---|---|---|---|---|
Females, n (%) | 69 (55.2) | 33 (54.1) | 24 (58.5) | 5 (45.5) | 3 (60) | 4 (57.1) |
Age at onset, years, median (range) | 34.1 (18.0–67.1) | 36.0 (18.0–67.1) | 34.6 (18.0–62.5) | 33.7 (18.0–42.1) | 45.7 (31.3–60.7) | 22.7 (19.4–53.7) |
Caucasian, n (%) | 120 (96) | 58 (95.1) | 40 (97.6) | 11 (100) | 5 (100) | 6 (85.7) |
Follow-up, years, median (range) | 4.5 (0.2–47) | 1.4 (0.4–47) | 5.7 (0.2–47) | 10.9 (2.1–21.2) | 2.5 (0.56–4.0) | 5.5 (0.2–19.3) |
Phenotype at onset, n (%) | ||||||
ON | 82 (65.6) | 61 (100) | 16 (39) | 0 | 0 | 5 (71.4) |
Myelitis | 25 (20) | 0 | 12 (29.3) | 11 (100) | 0 | 2 (28.6) |
ON and myelitis | 9 (7.2) | 0 | 9 (22) | 0 | 0 | 0 |
Encephalopathic/brainstem S. | 9 (7.2) | 0 | 4 (9.7) | 0 | 5 (100) | 0 |
EDSS at onset, median (range) | 3 (0–9) | 2.5 (0–4) | 3.25 (0–7.5) | 3 (1–6) | 4.5 (3.5–9) | 3.5 (3–8) |
EDSS 0–2.5 | 47 (38.2) | 30 (50) | 22 (55) | 4 (36.6) | 3 (60) | 5 (71.4) |
EDSS 3–5.5 | 64 (52) | 30 (50) | 32 (55) | 4 (36.6) | 3 (60) | 5 (71.3) |
EDSS ≥ 6.0 | 12 (9.8) | 0 | 6 (15) | 2 (18.2) | 2 (40) | 2 (28.6) |
aARR mean (SD) | 0.79 (0.91) | 0.80 (0.76) | 0.64 (0.76) | 0.46 (0.41) | 1.13 (1.06) | 1.78 (2.19) |
Acute treatment MTP/PLEX/IVIG), n (%) | 120 (96) | 61 (100) | 39 (95.1) | 10 (90.9) | 3 (60) | 7 (100) |
Paraclinical features, n (%) | ||||||
CSF OCB | 10/107 (9.4) | 1/49 (2.04) | 4/36 (11.1) | 3/11 (27.3) | 0/5 (0) | 2/6 (33.3) |
CSF pleiocytosis | 41/98 (41.8) | 7/46 (15.2) | 21/31 (67.7) | 6/10 (60) | 4/5 (80) | 3/6 (50) |
Abnormal brain MRI, at onset | 28/74 (37.8) | 7/38 (18.4) | 11/23 (47.8) | 3/6 (50) | 4/4 (100) | 3/3 (100) |
EDSS at the last follow-up, median (range) | 2 (0–7) | 1.0 (0–4) | 2 (0–7) | 2 (0–4) | 2.5 (1–3.5) | 3.5 (0–6.5) |
EDSS 0–2.5 | 86 (69.9) | 48 (80) | 26 (65) | 7 (63.6) | 3 (60) | 2 (28.6) |
EDSS 3–5.5 | 31 (25.2) | 12 (20) | 11 (27.5) | 4 (36.6) | 2 (40) | 2 (28.6) |
EDSS ≥ 6.0 | 6 (4.9) | 0 | 3 (7.5) | 0 | 0 | 3 (42.9) |
VA at the last follow-up | ||||||
VA ≥ 0.7 | 61/100 (61) | 36/61 (59) | 18/31 (58.1) | – | 3/3 (100) | 4/5 (80) |
VA > 0.2–0.6 | 21/100 (21) | 13/61 (21.3) | 8/31 (25.8) | – | 0 | 0 |
VA ≤ 0.2 | 18/100 (18) | 12/61 (19.7) | 5/31 (16.1) | – | 0 | 1/5 (20) |